



Image

Image  
1614

MAR 08 2004

TRANSMITTAL LETTER  
(General - Patent Pending)Docket No.  
2462-131US

In Re Application Of: Kazuya Hosokawa

Serial No.  
10/018,251Filing Date  
December 14, 2001

Examiner

Group Art Unit

Title: METHOD AND SUBSTANCE FOR INHIBITING REACTION BETWEEN ACTIVATED BLOOD  
COAGULATING FACTOR AND SUBSTRATETO THE COMMISSIONER FOR PATENTS:

Transmitted herewith is:

Search Report issued for the corresponding European Patent Application  
Transmittal of IDS  
IDS and 4 attachments

in the above identified application.

- No additional fee is required.
- A check in the amount of \_\_\_\_\_ is attached.
- The Director is hereby authorized to charge and credit Deposit Account No. \_\_\_\_\_ as described below.
- Charge the amount of \_\_\_\_\_
- Credit any overpayment.
- Charge any additional fee required.


  
Signature

Dated:

March 5, 2004

Richard C. Woodbridge  
Synnestvedt Lechner & Woodbridge LLP  
P.O. Box 592  
Princeton, NJ 08542  
609-924-3773 phone  
609-924-1811 fax

I certify that this document and fee is being deposited on March 5, 2004 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

  
Signature of Person Mailing Correspondence

Richard C. Woodbridge


Typed or Printed Name of Person Mailing Correspondence

CC:

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT  
(Under 37 CFR 1.97(b) or 1.97(c))**

Docket No.  
2462-131US

In Re Application Of: Kazuya Hosokawa



Serial No.  
10/018,251

Filing Date  
December 14, 2001

Examiner

Group Art Unit

Title: Method and Substance for Inhibiting Reaction Between Activated Blood Coagulating Factor and Substrate

Address to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**37 CFR 1.97(b)**

1.  The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2.  The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

- the statement specified in 37 CFR 1.97(e);


**OR**

- the fee set forth in 37 CFR 1.17(p).

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT  
(Under 37 CFR 1.97(b) or 1.97(c))**

Docket No.  
2462-131US

In Re Application: Kazuya Hosokawa



Serial No.  
10/018,251

Filing Date  
December 14, 2001

Examiner

Group Art Unit

**Method and Substance for Inhibiting Reaction Between Activated Blood Coagulating Factor and Substrate**

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- A check in the amount of \_\_\_\_\_ is attached.
- The Director is hereby authorized to charge and credit Deposit Account No. 23-3040 as described below.
- Charge the amount of \_\_\_\_\_
- Credit any overpayment.
- Charge any additional fee required.

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F:

\_\_\_\_\_  
(Date)

Signature

*Typed or Printed Name of Person Signing Certificate*

**Certificate of Mailing by First Class Mail**

I certify that this document and fee is being deposited on *March 5, 2004* with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*Richard C. Woodbridge*

*Signature of Person Mailing Correspondence*

Richard C. Woodbridge

*Typed or Printed Name of Person Mailing Certificate*

\*This certificate may only be used if paying by deposit account.

Dated:

*Signature*

Richard C. Woodbridge

Synnestvedt Lechner & Woodbridge LLP

P.O. Box 592

Princeton, NJ 08542

609-924-3773 phone

609-924-1811 fax

CC:

<b>INFORMATION DISCLOSURE CITATION</b> <small>(Use several sheets if necessary)</small>				Docket Number (Optional) 2462-131US		Application Number 10/018,251	
				Applicant(s) Kazuya Hosokawa			
				Filing Date December 14, 2001	Group Art Unit		
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<b>FOREIGN PATENT DOCUMENTS</b>							
REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
A	DE 199 07 099 A1	09/07/2000	Germany				
B	WO 00/49147	08/24/2000					
<b>OTHER DOCUMENTS</b> <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
C	HIGASHI SHOUICHI ET AL: "Molecular Mechanism of Tissue Factor-Mediated Acceleration of Factor VIIa Activity" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 43, 1996, pages 26569-26574						
D	HIGASHI ET AL; "Identification of Regions of Bovine Factor VII Essential for Binding To Tissue Factor" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, Baltimore, MD, US, vol. 269, no. 29, pages 18891-18898						
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							